These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 31210708)

  • 1. Predicting (side) effects for patients with inflammatory bowel disease: The promise of pharmacogenetics.
    Voskuil MD; Bangma A; Weersma RK; Festen EAM
    World J Gastroenterol; 2019 Jun; 25(21):2539-2548. PubMed ID: 31210708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease.
    Bangma A; Voskuil MD; Uniken Venema WTC; Brugge H; Hu S; Lanting P; Franke L; Dijkstra G; Festen EAM; Weersma RK
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1105-1115. PubMed ID: 32363635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on thiopurine pharmacogenetics in inflammatory bowel disease.
    Roberts RL; Barclay ML
    Pharmacogenomics; 2015 Jul; 16(8):891-903. PubMed ID: 26067482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
    Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
    Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacogenetics study of TPMT and ITPA genes detects a relationship with side effects and clinical response in patients with inflammatory bowel disease receiving Azathioprine.
    Zabala-Fernández W; Barreiro-de Acosta M; Echarri A; Carpio D; Lorenzo A; Castro J; Martínez-Ares D; Pereira S; Martin-Granizo I; Corton M; Carracedo A; Barros F
    J Gastrointestin Liver Dis; 2011 Sep; 20(3):247-53. PubMed ID: 21961091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to incorporate preemptive NUDT15 testing before starting thiopurines in inflammatory bowel disease in Asia and beyond: a review.
    Desai D; Jena A; Sharma V; Hibi T
    Expert Rev Clin Pharmacol; 2023; 16(7):643-653. PubMed ID: 37387532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
    Kakuta Y; Kawai Y; Okamoto D; Takagawa T; Ikeya K; Sakuraba H; Nishida A; Nakagawa S; Miura M; Toyonaga T; Onodera K; Shinozaki M; Ishiguro Y; Mizuno S; Takahara M; Yanai S; Hokari R; Nakagawa T; Araki H; Motoya S; Naito T; Moroi R; Shiga H; Endo K; Kobayashi T; Naganuma M; Hiraoka S; Matsumoto T; Nakamura S; Nakase H; Hisamatsu T; Sasaki M; Hanai H; Andoh A; Nagasaki M; Kinouchi Y; Shimosegawa T; Masamune A; Suzuki Y;
    J Gastroenterol; 2018 Sep; 53(9):1065-1078. PubMed ID: 29923122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression.
    Zelinkova Z; Derijks LJ; Stokkers PC; Vogels EW; van Kampen AH; Curvers WL; Cohn D; van Deventer SJ; Hommes DW
    Clin Gastroenterol Hepatol; 2006 Jan; 4(1):44-9. PubMed ID: 16431304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.
    Coenen MJ; de Jong DJ; van Marrewijk CJ; Derijks LJ; Vermeulen SH; Wong DR; Klungel OH; Verbeek AL; Hooymans PM; Peters WH; te Morsche RH; Newman WG; Scheffer H; Guchelaar HJ; Franke B;
    Gastroenterology; 2015 Oct; 149(4):907-17.e7. PubMed ID: 26072396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between thiopurine S-methyltransferase polymorphisms and thiopurine-induced adverse drug reactions in patients with inflammatory bowel disease: a meta-analysis.
    Liu YP; Wu HY; Yang X; Xu HQ; Li YC; Shi DC; Huang JF; Huang Q; Fu WL
    PLoS One; 2015; 10(3):e0121745. PubMed ID: 25799415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of inflammatory bowel disease.
    van den Bosch BJ; Coenen MJ
    Pharmacogenomics; 2021 Jan; 22(1):55-66. PubMed ID: 33305616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of thiopurine therapy in paediatric IBD patients.
    De Ridder L; Van Dieren JM; Van Deventer HJ; Stokkers PC; Van der Woude JC; Van Vuuren AJ; Benninga MA; Escher JC; Hommes DW
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1137-41. PubMed ID: 16611274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of thiopurines in inflammatory bowel disease.
    Derijks LJ; Wong DR
    Curr Pharm Des; 2010; 16(2):145-54. PubMed ID: 20205660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prospective Study Evaluating Metabolic Capacity of Thiopurine and Associated Adverse Reactions in Japanese Patients with Inflammatory Bowel Disease (IBD).
    Odahara S; Uchiyama K; Kubota T; Ito Z; Takami S; Kobayashi H; Saito K; Koido S; Ohkusa T
    PLoS One; 2015; 10(9):e0137798. PubMed ID: 26360046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics.
    Chang JY; Cheon JH
    Dig Dis Sci; 2019 Sep; 64(9):2395-2403. PubMed ID: 31290039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease.
    Walker GJ; Harrison JW; Heap GA; Voskuil MD; Andersen V; Anderson CA; Ananthakrishnan AN; Barrett JC; Beaugerie L; Bewshea CM; Cole AT; Cummings FR; Daly MJ; Ellul P; Fedorak RN; Festen EAM; Florin TH; Gaya DR; Halfvarson J; Hart AL; Heerasing NM; Hendy P; Irving PM; Jones SE; Koskela J; Lindsay JO; Mansfield JC; McGovern D; Parkes M; Pollok RCG; Ramakrishnan S; Rampton DS; Rivas MA; Russell RK; Schultz M; Sebastian S; Seksik P; Singh A; So K; Sokol H; Subramaniam K; Todd A; Annese V; Weersma RK; Xavier R; Ward R; Weedon MN; Goodhand JR; Kennedy NA; Ahmad T;
    JAMA; 2019 Feb; 321(8):773-785. PubMed ID: 30806694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TPMT and ITPA genetic variants in Lithuanian inflammatory bowel disease patients: Prevalence and azathioprine-related side effects.
    Steponaitiene R; Kupcinskas J; Survilaite S; Varkalaite G; Jonaitis L; Kiudelis G; Denapiene G; Valantinas J; Skieceviciene J; Kupcinskas L
    Adv Med Sci; 2016 Mar; 61(1):135-40. PubMed ID: 26674571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiopurine Methyltransferase Genetic Polymorphisms and Activity and Metabolic Products of Azathioprine in Patients with Inflammatory Bowel Disease.
    Pashazadeh P; Marjani A; Asadi J; Khoshnia M
    Endocr Metab Immune Disord Drug Targets; 2019; 19(4):541-547. PubMed ID: 30451123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomics and IBD: TPMT and thiopurines.
    Sandborn WJ
    Inflamm Bowel Dis; 2004 Feb; 10 Suppl 1():S35-7. PubMed ID: 15168829
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.